Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

7
90
0

Year Published

2019
2019
2020
2020

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 65 publications
(7 citation statements)
references
References 37 publications
(7 reference statements)
7
90
0
Order By: Relevance
“…In the EFFIPAP study, a randomized controlled trial comparing PCs in plasma, in PAS or inactivated using Amotosalen/UVA, the rate of allergic reaction was also found to be lower in the group of Amotosalen/UVA inactivated PCs. Their hemostatic efficacy was non‐inferior when compared with PCs in PAS but slightly reduced in comparison with PCs in native plasma . However, due to the global benefice of PCs in PAS, PCs in native plasma are almost no longer used in France.…”
Section: Discussionmentioning
confidence: 99%
“…In the EFFIPAP study, a randomized controlled trial comparing PCs in plasma, in PAS or inactivated using Amotosalen/UVA, the rate of allergic reaction was also found to be lower in the group of Amotosalen/UVA inactivated PCs. Their hemostatic efficacy was non‐inferior when compared with PCs in PAS but slightly reduced in comparison with PCs in native plasma . However, due to the global benefice of PCs in PAS, PCs in native plasma are almost no longer used in France.…”
Section: Discussionmentioning
confidence: 99%
“…Contaminated units can be detected by screening PC samples by culture methods and by visually inspecting components, or by rapid tests immediately before transfusion . The bacterial load can be reduced using pathogen reduction techniques that have been developed and introduced in some countries as an ultimate solution to this issue . However, each of these methodologies has advantages and disadvantages with respect to clinical outcomes; workload on staff not only at blood facilities, but also medical institutions that deal with the mitigating procedures; time constraints; complicated logistics derived from the short shelf life of PC; and the cost of introducing and maintaining mitigation measures.…”
mentioning
confidence: 99%
“…The latter studies provided the necessary background for the implementation of some observational studies and of 10 randomised clinical trials (RCTs) aimed at the comparison of PRT versus standard platelets in haematology patients. Table II shows in chronological order the sample size, the post-transfusion platelet count increments and the number of patients developing bleeding episodes in the 7 RCTs using the Intercept system (van Rhenen et al, 2003: McCullough et al, 2004Janetzko et al, 2005;Snyder et al, 2005;Kerkhoffs et al, 2010;Lozano et al, 2011;Rebulla et al, 2017;Garban et al, 2018) and in the 3 RCTs using the Mirasol system (Mirasol Clinical Evaluation Study Group, 2010;Rebulla et al, 2017;van der Meer et al, 2018).…”
Section: Autologous Platelet Transfusion Studies In Healthy Subjects mentioning
confidence: 99%